vs
Side-by-side financial comparison of Honest Company, Inc. (HNST) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $78.1M, roughly 2.0× Honest Company, Inc.). On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -19.7%).
The Honest Company, Inc. is an American digital-first consumer goods company, based in Los Angeles and founded by actress Jessica Alba, Christopher Gavigan, and Brian Lee. The company had $319 million in 2021 sales, and was valued at roughly $550 million as of February 2022. Carla Vernón, Chief Executive Officer, is one of the first Afro-Latina CEOs of a U.S. publicly traded company. The Honest Company has raised multiple rounds of venture capital, and went public via an initial public offeri...
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
HNST vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $78.1M | $158.6M |
| Net Profit | — | $112.9M |
| Gross Margin | 42.6% | — |
| Operating Margin | 56.6% | 70.2% |
| Net Margin | — | 71.2% |
| Revenue YoY | -19.7% | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | $0.00 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $78.1M | — | ||
| Q4 25 | $88.0M | — | ||
| Q3 25 | $92.6M | — | ||
| Q2 25 | $93.5M | — | ||
| Q1 25 | $97.3M | $158.6M | ||
| Q4 24 | $99.8M | $22.6M | ||
| Q3 24 | $99.2M | — | ||
| Q2 24 | $93.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-23.6M | — | ||
| Q3 25 | $758.0K | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $3.3M | $112.9M | ||
| Q4 24 | $-809.0K | $-10.5M | ||
| Q3 24 | $165.0K | — | ||
| Q2 24 | $-4.1M | — |
| Q1 26 | 42.6% | — | ||
| Q4 25 | 15.7% | — | ||
| Q3 25 | 37.3% | — | ||
| Q2 25 | 40.4% | — | ||
| Q1 25 | 38.7% | — | ||
| Q4 24 | 38.8% | — | ||
| Q3 24 | 38.7% | — | ||
| Q2 24 | 38.3% | — |
| Q1 26 | 56.6% | — | ||
| Q4 25 | -27.5% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 2.6% | 70.2% | ||
| Q4 24 | -1.0% | -60.4% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | -4.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | -26.8% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 3.3% | 71.2% | ||
| Q4 24 | -0.8% | -46.4% | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | -4.4% | — |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $-0.21 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.03 | — | ||
| Q1 25 | $0.03 | $1.90 | ||
| Q4 24 | $-0.01 | $-0.15 | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.4M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $169.1M | $350.1M |
| Total Assets | $214.9M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $90.4M | — | ||
| Q4 25 | $89.6M | — | ||
| Q3 25 | $71.5M | — | ||
| Q2 25 | $72.1M | — | ||
| Q1 25 | $72.8M | $274.8M | ||
| Q4 24 | $75.4M | $128.0M | ||
| Q3 24 | $53.4M | — | ||
| Q2 24 | $36.6M | — |
| Q1 26 | $169.1M | — | ||
| Q4 25 | $169.7M | — | ||
| Q3 25 | $190.2M | — | ||
| Q2 25 | $187.0M | — | ||
| Q1 25 | $180.4M | $350.1M | ||
| Q4 24 | $174.3M | $229.0M | ||
| Q3 24 | $133.9M | — | ||
| Q2 24 | $129.7M | — |
| Q1 26 | $214.9M | — | ||
| Q4 25 | $225.4M | — | ||
| Q3 25 | $241.5M | — | ||
| Q2 25 | $249.0M | — | ||
| Q1 25 | $265.3M | $406.9M | ||
| Q4 24 | $247.4M | $271.6M | ||
| Q3 24 | $209.2M | — | ||
| Q2 24 | $200.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | 0.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $19.3M | — | ||
| Q3 25 | $-504.0K | — | ||
| Q2 25 | $-745.0K | — | ||
| Q1 25 | $-2.9M | $131.8M | ||
| Q4 24 | $-16.8M | $-23.2M | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $2.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $18.1M | — | ||
| Q3 25 | $-624.0K | — | ||
| Q2 25 | $-826.0K | — | ||
| Q1 25 | $-3.0M | $131.7M | ||
| Q4 24 | $-17.2M | $-23.2M | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $2.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | -0.7% | — | ||
| Q2 25 | -0.9% | — | ||
| Q1 25 | -3.1% | 83.0% | ||
| Q4 24 | -17.2% | -102.7% | ||
| Q3 24 | 15.1% | — | ||
| Q2 24 | 3.1% | — |
| Q1 26 | 0.6% | — | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | 0.1% | ||
| Q4 24 | 0.3% | 0.2% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.66× | — | ||
| Q2 25 | -0.19× | — | ||
| Q1 25 | -0.90× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | 91.42× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
